Marianne Notter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marianne Notter has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Hyman Tannenbaum
Rheumatic Disease Center of Montréal, Montréal, Canada
1 shared publication - Jean-Yves Reginster
Protein Research Chair, Department of Biochemistry, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
1 shared publication - Neha P Patel
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
1 shared publication - Peter Sallstig
Immunology & Infectious Disease Therapeutic Area, Novartis Pharma AG, Lichtstrasse 35, CH-4056, Basel, Switzerland
1 shared publication - Roy Fleischmann
University of Texas Southwestern Medical Center, Dallas, Texas, USA
1 shared publication
Latest Publications
- Open Access
- 7 March 2008
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 9 (1) , 32
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA, the present study compared the effects of lumiracoxib at doses of 100 mg once daily (o.d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year.
- 7 March 2008
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 9 (1) , 32
Open AccessLong-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
The efficacy, safety and tolerability of lumiracoxib, a novel selective cyclooxygenase-2 (COX-2) inhibitor, has been demonstrated in previous studies of patients with osteoarthritis (OA). As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA, the present study compared the effects of lumiracoxib at doses of 100 mg once daily (o.d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year.